依諾妥珠單抗
依諾妥珠單抗（INN：Enoblituzumab；開發代號：MGA271）是一種單克隆抗體，設計用於治療癌症。[1]該藥物是一種人源化IgG1κ單克隆抗體，可識別人類B7-H3（免疫調節劑B7家族的成員）。[2]
| 單克隆抗體 | |
|---|---|
| 種類 | ? |
| 目標 | B7-H3 |
| 臨床資料 | |
| 其他名稱 | MGA271 |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 1353485-38-7 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6474H9990N1726O2030S42 |
| 摩爾質量 | 145,829.71 g·mol−1 |
該藥物由MacroGenics公司開發。[3]
參考資料
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Enoblituzumab, American Medical Association.
- ^ Aggarwal, Charu; Prawira, Amy; Antonia, Scott; Rahma, Osama; Tolcher, Anthony; Cohen, Roger B.; Lou, Yanyan; Hauke, Ralph; Vogelzang, Nicholas; P Zandberg, Dan; Kalebasty, Arash Rezazadeh. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. Journal for Immunotherapy of Cancer. 2022-04, 10 (4) [2024-03-12]. ISSN 2051-1426. PMC 9006844
. PMID 35414591. doi:10.1136/jitc-2021-004424. （原始內容存檔於2024-06-16）.
- ^ Enoblituzumab (anti-B7-H3) – MacroGenics. macrogenics.com. [2024-03-12]. （原始內容存檔於2024-03-12）.
